US Human Microbiome Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143353
- Pages: 225
-
Format:
Short Description
U.S. Human Microbiome Market, By Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs, Supplements, Fecal Microbiota Transplant, and Others), Application (Therapeutic and Diagnostic), Disease (Infectious Disease, Dermatological Disorders, Autoimmune Disorder, Metabolic Disorder, Gastrointestinal Disorders, Cancer, Mental Disorders, Clostridioides Difficile Infection, Primary Hyperoxyureasolution-Phase, and Others), Technology (Genomics, Proteomics, and Metabolomics), Type (Small Molecule and Biologic), End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Hypermarket/Supermarket, Clinics, and Others), Distributor (Direct Tender and Retail Sales), Country (U.S.) Industry Trends and Forecast to 2029
Market Definition
Microbiota means the microbial taxa associated with humans, and microbiome means the catalog of these microbes and their genes. The aggregation of all the microbiota reside on or within human tissues and bio fluids along with corresponding anatomical sites in which they reside, including the skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract, and others. The human microbiota consists of the 10-100 trillion symbiotic microbial cells harbored by each person, primarily bacteria in the gut. The human microbiome consists of the genes these cells harbor.
The microbiome is the genetic material of all the microbes - bacteria, fungi, protozoa, and viruses - that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome. The most widely used method of identification of microbiome analysis is 16s rRNA sequencing. Identification and understanding of these microbiotas have led to the application of these microorganisms in the betterment of human health via various products such as probiotics, prebiotics, and other associated drugs.
Market Segmentation
U.S. human microbiome market is categorized into seven notable segments based on product, application, disease, technology, type, end user, and distributor. In 2022, product segment is expected to dominate the market due to rise in incidence and prevalence of lifestyle disorders and chronic diseases.
On the basis of product, the market is segmented into probiotics, prebiotics, diagnostic tests, drugs, supplements, fecal microbiota transplant, and others
On the basis of application, the market is segmented into therapeutic and diagnostic
On the basis of disease, the market is segmented into infectious disease, dermatological disorders, autoimmune disorder, metabolic disorder, gastrointestinal disorders, cancer, mental disorders, C. Difficile infection, primary hyperoxyureasolution-phase, and others
On the basis of technology, the market is segmented into genomics, proteomics and metabolomics
On the basis of type, the market is segmented into small molecule and biologic
On the basis of end user, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, hypermarket/supermarket, clinics, and others
On the basis of distributor, the market is segmented into direct tender and retail sales
Market Players
The key market players for U.S. human microbiome market are listed below:
4D pharma plc
Evelo Biosciences, Inc.
Viome Life Sciences, Inc.
Finch Therapeutics Group, Inc.
OptiBiotix HEALTH PLC
BiomX
Sun Genomics
Metabiomics
Osel Inc
Ferring B.V.
Merck KGaA
Assembly Biosciences, Inc.
Synthetic Biologics, Inc.
FlightPath Biosciences, Inc.
Vedanta Biosciences, Inc.
Second Genome
TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF U.S. HUMAN MICROBIOME MARKET 15
1.4 LIMITATIONS 17
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT LIFELINE CURVE 28
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.9 DBMR MARKET POSITION GRID 30
2.10 MARKET APPLICATION COVERAGE GRID 31
2.11 VENDOR SHARE ANALYSIS 32
2.12 SECONDARY SOURCES 33
2.13 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 37
4.1 PESTEL 39
4.2 PORTER'S FIVE FORCES MODEL 40
4.3 GLOBAL HUMAN MICROBIOME MARKET ANALYSIS 41
4.4 GUT MICROBIOME AND DIAGNOSTIC 42
5 EPIDEMIOLOGY 43
5.1 EPIDEMIOLOGY CANCER 43
5.2 EPIDEMIOLOGY DERMATOLOGICAL DISORDERS 44
5.3 EPIDEMIOLOGY GASTRIC DISORDERS 45
5.4 EPIDEMIOLOGY IMMUNE DISORDERS 46
5.5 EPIDEMIOLOGY METABOLIC DISORDERS 47
6 INDUSTRY INSIGHTS 48
6.1 DEMOGRAPHIC TRENDS 48
6.2 KEY PRICING STRATEGIES 48
7 INDUSTRY INSIGHT 49
7.1 PATENT ANALYSIS 49
7.2 PATENT FLOW DIAGRAM 50
8 REGULATORY FRAMEWORKS 51
8.1 UNITED STATES 51
8.2 EUROPE 52
9 MARKET OVERVIEW 54
9.1 DRIVERS 56
9.1.1 RISING PREVALENCE OF LIFESTYLE AND CHRONIC DISEASES 56
9.1.2 HUMAN MICROBIOME THERAPEUTIC DEVELOPMENT FOR DISEASE TREATMENT 56
9.1.3 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING 57
9.2 RESTRAINTS 57
9.2.1 BARRIERS PROVING THE CAUSAL LINK BETWEEN DYSBIOSIS AND DISEASES 57
9.2.2 LACK OF TECHNOLOGY EXPERTISE 58
9.3 OPPORTUNITIES 58
9.3.1 RISE IN HEALTHCARE EXPENDITURE 58
9.3.2 INCREASING RESEARCH AND DEVELOPMENT 59
9.4 CHALLENGE 60
9.4.1 RISK ASSOCIATED WITH HUMAN MICROBIOME PRODUCTS 60
10 U.S. HUMAN MICROBIOME MARKET, BY PRODUCT 61
10.1 OVERVIEW 62
10.2 PROBIOTICS 65
10.2.1 BRANDED 65
10.2.1.1 OPTIPAC-PREBIOTICS FIBRE 66
10.2.1.2 ENZYMEDICA-PREBIOTICS DRINK MIX 66
10.2.1.3 SWEETBIOTIX 66
10.2.1.4 OTHERS 66
10.2.2 GENERICS 66
10.3 PREBIOTICS 66
10.3.1 BRANDED 67
10.3.1.1 BIOM PROBIOTIC 67
10.3.1.2 BIOM D FEND 67
10.3.1.3 FLORE GUT MICROBIOME TEST 68
10.3.1.4 REVITIFY 68
10.3.1.5 SYMBIOTIC YOGURT 68
10.3.1.6 SYMBIOTIC 68
10.3.1.7 LPLDL 68
10.3.1.8 LPGOS 68
10.3.1.9 OTHERS 68
10.3.2 GENERICS 69
10.4 SUPPLEMENTS 69
10.4.1 CHOLBIOME 70
10.4.2 LPGOS 70
10.4.3 WELL BIOME 70
10.4.4 FLORE BOOM 70
10.4.5 FLORE DEFENCE 70
10.4.6 FLORE BALANCE 70
10.4.7 BIOM 70
10.4.8 REVITIFY 71
10.4.9 FLORE 71
10.4.10 BIOM D FEND 71
10.4.11 SLIM BIOME 71
10.4.12 OTHERS 71
10.5 DIAGNOSTICS TESTS 71
10.5.1 FLORE GUT MICROBIOME TEST 72
10.5.2 FLORE 360 72
10.5.3 BIOME MICROBIOME TEST 72
10.5.4 SUPER GUT MICROBIOME HEALTH TEST 73
10.5.5 HEALTH INTELLIGENCE TEST 73
10.5.6 GUT INTELLIGENCE TEST 73
10.5.7 X MARKER 73
10.5.8 ATLAS MICROBIOME TEST 73
10.5.9 1TEST 1 73
10.5.10 LIFE KIT 73
10.5.11 FOR A 74
10.5.12 OTHERS 74
10.6 DRUGS 74
10.6.1 OXABACT 75
10.6.2 SINTAX 75
10.6.3 SYNBIOTIC YOGURT 75
10.6.4 SYNBIOTIC 7 75
10.6.5 MICRORX 75
10.6.6 SLIM BIOME 75
10.6.7 SLIM BIOME MEDICAL 75
10.6.8 LPLDL 76
10.6.9 CHOLBIOME 76
10.6.10 OTHERS 76
10.7 FECAL MICROBIOTA TRANSPLANT 76
10.8 OTHERS 76
11 U.S. HUMAN MICROBIOME MARKET, BY APPLICATION 78
11.1 OVERVIEW 79
11.2 THERAPEUTIC 82
11.2.1 SINGLE STRAIN OR MULTI-STRAIN CONSORTIA 82
11.2.2 LIQUID OR DRIED BULK DRUG SUBSTANCE 82
11.2.3 SOLID ORAL DOSE 83
11.2.4 OTHERS 83
11.3 DIAGNOSTIC 83
11.3.1 IRRITABLE BOWEL SYNDROME 84
11.3.2 LEAKY GUT SYNDROME 84
11.3.3 DIABETES 84
11.3.4 BACTERIAL VAGINOSIS 84
11.3.5 GINGITIVIS 84
11.3.6 TRICHOMONIASIS 85
11.3.7 VAGINAL CANDIDIASIS 85
12 U.S. HUMAN MICROBIOME MARKET, BY DISEASE 86
12.1 OVERVIEW 87
12.2 INFECTIOUS DISEASE 90
12.2.1 HELICOBACTER PYLORI 90
12.2.2 C. DIFFICILE INFECTIONS 90
12.2.3 BACTERIAL VAGINOSIS 90
12.2.4 OTHERS 91
12.3 GASTROINTESTINAL DISORDERS 91
12.4 C. DIFFICILE INFECTION 91
12.5 METABOLIC DISORDER 91
12.5.1 DIABETES 92
12.5.2 OBESITY 92
12.5.3 ENDOCRINE 92
12.5.4 NON ALCOHOLIC LIVER DISEASE 93
12.6 AUTOIMMUNE DISORDER 93
12.7 CANCER 93
12.8 MENTAL DISORDER 93
12.9 DERMATOLOGICAL DISORDERS 94
12.9.1 ATOPIC DERMATITIS 94
12.9.2 ROSACEA 94
12.9.3 ACNE 95
12.9.4 OTHERS 95
12.10 PRIMARY HYPEROXYUREASOLUTION-PHASE 95
12.11 OTHERS 96
13 U.S. HUMAN MICROBIOME MARKET, BY TECHNOLOGY 97
13.1 OVERVIEW 98
13.2 GENOMICS 100
13.2.1 SEQUENCING 101
13.2.1.1 16S RRNA SEQUENCING METHOD 101
13.2.1.2 SHOTGUN METAGENOMICS SEQUENCING 101
13.2.1.3 WHOLE GENOME SEQUENCING 102
13.2.1.4 OTHER 102
13.2.2 POLYMERASE CHAIN REACTION 102
13.2.3 OTHER GENOMIC TECHNIQUES 102
13.2.4 ORGAN TRANSPLANTATION 102
13.2.5 OTHER CLINICAL APPLICATION 102
13.3 PROTEOMICS 103
13.3.1 EXPRESSION PROTEOMICS 103
13.3.2 FUNCTIONAL PROTEOMICS 103
13.3.3 STRUCTURAL PROTEOMICS 103
13.4 METABOLIMICS 104
13.4.1 TARGETED ANALYSIS 104
13.4.2 METABOLITE PROFILING 104
13.4.3 METABOLIC FINGERPRINTING 105
14 U.S. HUMAN MICROBIOME MARKET, BY TYPE 106
14.1 OVERVIEW 107
14.2 SMALL MOLECULE 109
14.3 BIOLOGIC 110
15 U.S. HUMAN MICROBIOME MARKET, BY END USER 111
15.1 OVERVIEW 112
15.2 ONLINE PHARMACIES 114
15.3 HYPERMARKET & SUPERMARKET 115
15.4 RETAIL PHARMACIES 115
15.5 HOSPITAL PHARMACIES 115
15.6 CLINICS 116
15.7 OTHERS 116
16 U.S. HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL 117
16.1 OVERVIEW 118
16.2 RETAIL SALES 120
16.3 DIRECT TENDERS 120
17 U.S. HUMAN MICROBIOME MARKET: COMPANY LANDSCAPE 122
17.1 COMPANY SHARE ANALYSIS: U.S. 122
18 COMPANY PROFILE 123
18.1 OPTIBIOTIX HEALTH PLC 123
18.1.1 COMPANY SNAPSHOT 123
18.1.2 PRODUCT PORTFOLIO 123
18.1.3 RECENT DEVELOPMENT 123
18.2 MERCK KGAA 124
18.2.1 COMPANY SNAPSHOT 124
18.2.2 PRODUCT PORTFOLIO 124
18.2.3 RECENT DEVELOPMENTS 124
18.3 FINCH THERAPEUTICS GROUP, INC 125
18.3.1 COMPANY SNAPSHOT 125
18.3.2 PIPELINE PRODUCT PORTFOLIO 125
18.3.3 RECENT DEVELOPMENT 125
18.4 FERRING B.V. 126
18.4.1 COMPANY SNAPSHOT 126
18.4.2 PIPELINE PRODUCT PORTFOLIO 126
18.4.3 RECENT DEVELOPMENTS 126
18.5 ATLAS BIOMED GROUP LIMITED 127
18.5.1 COMPANY SNAPSHOT 127
18.5.2 PRODUCT PORTFOLIO 127
18.5.3 RECENT DEVELOPMENTS 127
18.6 ENTEROME 128
18.6.1 COMPANY SNAPSHOT 128
18.6.2 PIPELINE PRODUCT PORTFOLIO 128
18.6.3 RECENT DEVELOPMENTS 128
18.7 ASSEMBLY BIOSCIENCES, INC. 130
18.7.1 COMPANY SNAPSHOT 130
18.7.2 PIPELINE PRODUCT PORTFOLIO 130
18.7.3 RECENT DEVELOPMENTS 130
18.8 BIOMX 132
18.8.1 COMPANY SNAPSHOT 132
18.8.2 PIPELINE PRODUCT PORTFOLIO 132
18.8.3 RECENT DEVELOPMENTS 132
18.9 EMBION TECHNOLOGIES S.A. 133
18.9.1 COMPANY SNAPSHOT 133
18.9.2 PIPELINE PRODUCT PORTFOLIO 133
18.9.3 RECENT DEVELOPMENTS 133
18.10 EVELO BIOSCIENCES, INC. 134
18.10.1 COMPANY SNAPSHOT 134
18.10.2 PIPELINE PRODUCT PORTFOLIO 134
18.10.3 RECENT DEVELOPMENTS 134
18.11 FLIGHTPATH BIOSCIENCES, INC. 135
18.11.1 COMPANY SNAPSHOT 135
18.11.2 PIPELINE PRODUCT PORTFOLIO 135
18.11.3 RECENT DEVELOPMENTS 135
18.12 GNUBIOTICS SCIENCES 136
18.12.1 COMPANY SNAPSHOT 136
18.12.2 PIPELINE PRODUCT PORTFOLIO 136
18.12.3 RECENT DEVELOPMENTS 136
18.13 IMMURON 138
18.13.1 COMPANY SNAPSHOT 138
18.13.2 PIPELINE PRODUCT PORTFOLIO 138
18.13.3 RECENT DEVELOPMENTS 138
18.14 LUXIA SCIENTIFIC 139
18.14.1 COMPANY SNAPSHOT 139
18.14.2 PRODUCT PORTFOLIO 139
18.14.3 RECENT DEVELOPMENTS 139
18.15 METABIOMICS 140
18.15.1 COMPANY SNAPSHOT 140
18.15.2 PRODUCT PORTFOLIO 140
18.15.3 RECENT DEVELOPMENTS 140
18.16 OSEL INC 141
18.16.1 COMPANY SNAPSHOT 141
18.16.2 PRODUCT PORTFOLIO 141
18.16.3 RECENT DEVELOPMENT 141
18.17 OXTHERA. 142
18.17.1 COMPANY SNAPSHOT 142
18.17.2 PIPELINE PRODUCT PORTFOLIO 142
18.17.3 RECENT DEVELOPMENTS 142
18.18 SECOND GENOME 144
18.18.1 COMPANY SNAPSHOT 144
18.18.2 PIPELINE PRODUCT PORTFOLIO 144
18.18.3 RECENT DEVELOPMENTS 144
18.19 SERES THERAPEUTICS 146
18.19.1 COMPANY SNAPSHOT 146
18.19.2 PIPELINE PRODUCT PORTFOLIO 146
18.19.3 RECENT DEVELOPMENTS 146
18.20 SUN GENOMICS 148
18.20.1 COMPANY SNAPSHOT 148
18.20.2 PRODUCT PORTFOLIO 148
18.20.3 RECENT DEVELOPMENTS 148
18.21 SYNTHETIC BIOLOGICS, INC.. 149
18.21.1 COMPANY SNAPSHOT 149
18.21.2 PIPELINE PRODUCT PORTFOLIO 149
18.21.3 RECENT DEVELOPMENTS 150
18.22 SYNLOGIC 151
18.22.1 COMPANY SNAPSHOT 151
18.22.2 PIPELINE PRODUCT PORTFOLIO 151
18.22.3 RECENT DEVELOPMENTS 152
18.23 VEDANTA BIOSCIENCES, INC. 153
18.23.1 COMPANY SNAPSHOT 153
18.23.2 PIPELINE PRODUCT PORTFOLIO 153
18.23.3 RECENT DEVELOPMENTS 153
18.24 VIOME LIFESCIENCES, US 155
18.24.1 COMPANY SNAPSHOT 155
18.24.2 PRODUCT PORTFOLIO 155
18.24.3 RECENT DEVELOPMENT 155
18.25 YSOPIA BIOSCIENCE 156
18.25.1 COMPANY SNAPSHOT 156
18.25.2 PIPELINE PRODUCT PORTFOLIO 156
18.25.3 RECENT DEVELOPMENT 156
18.26 4D PHARMA PLC 157
18.26.1 COMPANY SNAPSHOT 157
18.26.2 PRODUCT PORTFOLIO 157
18.26.3 RECENT DEVELOPMENTS 157
19 QUESTIONNAIRE 158
20 RELATED REPORTS 161
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
